Mancare Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.90 M
as on 24-10-2024
- Company Age 28 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.95 Cr
as on 24-10-2024
- Revenue 0.53%
(FY 2023)
- Profit -20.21%
(FY 2023)
- Ebitda -15.24%
(FY 2023)
- Net Worth 10.53%
(FY 2023)
- Total Assets -3.33%
(FY 2023)
About Mancare Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹9.95 Cr.
Hasmukh Shah and Kalpesh Shah serve as directors at the Company.
- CIN/LLPIN
U24239MH1996PTC101774
- Company No.
101774
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Aug 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationThane, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mancare Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hasmukh Shah  | Director | 09-Aug-1996 | Current |
| Kalpesh Shah | Director | 05-Dec-1996 | Current |
Financial Performance of Mancare Pharmaceuticals.
Mancare Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.53% increase. The company also saw a substantial fall in profitability, with a 20.21% decrease in profit. The company's net worth Soared by an impressive increase of 10.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mancare Pharmaceuticals?
In 2023, Mancare Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹99.50 M
₹0
Charges Breakdown by Lending Institutions
- Union Bank Of India : 9.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 May 2009 | Union Bank Of India | ₹2.50 M | Open |
| 26 May 2009 | Union Bank Of India | ₹9.35 Cr | Open |
| 26 May 2009 | Union Bank Of India | ₹3.50 M | Open |
How Many Employees Work at Mancare Pharmaceuticals?
Mancare Pharmaceuticals has a workforce of 8 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mancare Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mancare Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.